ACC Revises Obesity Control Strategies in Heart Failure
A new Scientific Statement from the American College of Cardiology (ACC) has named two anti-obesity drugs as options for symptom control in patients with heart failure.
The benefit for these incretin mimics, semaglutide and tirzepatide, is attributed to symptom control, according to the statement. The document, published on June 13 in the Journal of the American College of Cardiology , states that each medication has the potential to reduce cardiovascular (CV) events related to heart failure, but neither has yet done so on the basis of level 1 evidence.
The new recommendation appl ies only to heart failure with preserved ejection fraction (HFpEF). The safety and efficacy of these drugs has yet to be established for heart failure with reduced ejection fraction (HFrEF), according to the ACC statement.
The new anti-obesity drugs were approved initially for type 2 diabetes. On the basis of substantial weight loss and their relative safety, the FDA subsequently granted indications for obesity alone in patients with at least one additional obesity-related comorbidity, such as hypertension, dyslipidemia, or obstructive sleep apnea.
Current Indications for Incretin Mimetics
Semaglutide has an indication for patients with CV disease, but not heart failure specifically, and obesity on the basis of the 2023 SELECT trial. Tirzepatide has an indication for patients with sleep apnea and obesity in the absence of diabetes on the basis of the 2024 SURMOUNT-OSA trial.
In the 2023 STEP-HFpEF trial with semaglutide and the 2025 SUMMIT trial with tirzepatide, each agent was associated with a reduction in symptoms of heart failure in patients with HFpEF. However, the study designs and outcomes differed.
For one, the HFpEF entry criterion was a left ventricular ejection fraction ≥ 45% in STEP-HFpEF but ≥ 50% in the SUMMIT trial. In dual primary endpoints, both included changes in the Kansas City Cardiomyopathy Questionnaire (KCCQ), but the first of the two trials evaluated weight change, while the second evaluated a composite endpoint of CV death and heart failure-related events.
By listing semaglutide and tirzepatide as options within a comprehensive review of the treatment of obesity in heart failure, the new document steps in front of current regulatory guidance. In a table that juxtaposed FDA-approved indications for these drugs to evidence-based benefits as defined by the statement, only the latter identifies a role in heart failure.
'The intent of the Writing Committee in including this table was to highlight that there are no FDA-approved heart failure indications for the use of incretin-based anti-obesity medications to date,' said Michelle M. Kittleson, MD, PhD, director of Heart Failure Research at Cedars-Sinai Medical Center in Los Angeles, who chaired the committee.
'While clinicians might identify individuals with heart failure who meet the standard FDA-approved indications, it is important to also identify which of those patients also meet inclusion criteria for th e heart failure trials were benefit was shown,' Kittleson said.
Semaglutide acts on the GLP-1 receptor alone. Tirzepatide is an agonist of both the GLP-1 receptor and glucose-dependent insulinotropic polypeptide. Both drugs are associated with strong signals of CV benefit overall and in heart failure specifically, even if the evidence in HFpEF is 'stronger,' according to the statement.
Incretin drugs mimic hormones that downregulate appetite. They are considered third-generation anti-obesity agents on the basis of their targeted mechanism and a low relative risk for adverse events. More than a dozen such agents are now in various stages of development, according to the ACC statement.
Semaglutide and Tirzepatide Trials Differ
In the STEP-HFpEF trial, which like SUMMIT trial, was placebo controlled, the 7.8-point gain ( P <.0001) in the KCCQ on active therapy vs placebo was statistically significant, as was the percent body weight loss (-13.3% vs -2.6%; P < .001).
The SUMMIT trial found a 6.9-point gain in the KCCQ score ( P < .001) relative to placebo, while the rate the composite event endpoint of CV death from events associated with heart failure was lower (9.9% vs 15.3%; P = .026), but CV deaths occurred in only 13 patients. Heart failure events were observed in 81 patients over 2 years of follow-up.
In both studies, significant gains in the secondary endpoints of physical and exercise function were associated with the assigned weight-loss drug.
On the evidence so far, the authors of the ACC statement concluded that despite the marginal benefit observed in the SUMMIT trial, no firm conclusions can be made about the ability of incretin therapies to protect patients with HFpEF against hard endpoints, Kittleson said.
Until more data are available, she cautioned against the risk for 'indication creep,' the willingness to offer these drugs for potential benefits that have yet to be confirmed. Still, she added, 'the goal of the writing group was to strike a tone of cautious optimism guided by the available data.'
Part of this optimism has been fueled by the 2023 SELECT trial, which enrolled more than 17,000 patients with overweight with CV disease but no diabetes. Relative to placebo, semaglutide was associated with a 20% reduction ( P < .001) in the composite primary endpoint of CV death, nonfatal myocardial infarction, and nonfatal stroke. Only 24% of patients in this study had heart failure, but the risk reduction in this group was consistent with that of the study population as a whole.
Obesity is listed in most guidelines, including a 2024 ACC Expert Consensus Decision Pathway for Treatment of HFrEF, as a common comorbidity of heart failure and potentially treatable risk factor for symptoms and progression of the condition. However, the new statement differs from prior guidelines. Typically, lifestyle modifications are identified as a first step toward weight loss.
'Patients should not be required to try and fail lifestyle changes prior to initiating pharmacotherapy,' according to Olivia Gilbert, MD, a cardiologist specializing in advanced heart failure and transplantation at Atrium Wake Forest Baptist Medical Center, in Wake Forest, North Carolina. Although Gilbert was not part of the writing committee for the new document, she has been involved in developing clinical guidance statements for the ACC.
The incretin therapies are more effective than lifestyle medications and safer than procedure-based weight-loss interventions, Gilbert said, providing a basis for suggesting they can be considered first line therapy for patients with symptomatic HFpEF.
'Lifestyle interventions should always be offered in conjunction with obesity medications,' she said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
20 minutes ago
- Medscape
PCP Toolkit for Treating Patients With Respiratory Diseases
Primary care physicians (PCPs) regularly encounter respiratory issues, from the common cold to asthma, chronic obstructive pulmonary disease ( COPD), and more. These conditions can, at times, be diagnosed fairly quickly and easily. But sometimes, ubiquitous symptoms can make differentiating diagnoses difficult. Lung diseases can range from very minor to critical, so you don't want to waste any time in the diagnostic process. It's important, then, to know what tools PCPs have at hand and how to best apply them. This is especially true as many lung diseases also have comorbidities. 'Patients with COPD often also have high blood pressure, high cholesterol, and left-sided heart disease,' said Jeffrey Marshall, MD, pulmonologist at University of Maryland Baltimore Washington Medical Center in Glen Burnie, Maryland. It's also common for patients with respiratory diseases to experience concomitant mental health struggles, according to Marshall. For instance, high rates of anxiety are often found in patients with advanced lung disease. 'All these comorbid conditions can both exacerbate the patient's underlying pulmonary disease or be confused as an exacerbation of that pulmonary disease,' he said. Respiratory complaints — like difficulty breathing and chest pain — are among the most common reasons patients visit the emergency room. While these complaints may fall within respiratory illnesses, there are often other explanations for a patient's symptoms. Learning to discern these differences can be an important skill set as a PCP. That said, it's also important to know when to refer to a specialist. 'Early recognition and timely referral can significantly improve patient outcomes,' said Tejaswini Kulkarni, MD, associate professor of medicine and director of the Interstitial Lung Disease Program at The University of Alabama at Birmingham. Here's what you need to know to treat and guide your patients presenting with respiratory issues. PCP Toolkit The first step to having a handle on respiratory issues with your patients is taking a comprehensive medical history. For patients who have been already diagnosed with a respiratory condition, 'it's important to reinforce proper disease management and medication adherence,' said Marshall. 'Exposures, triggers, prior personal history, and a detailed family history are all important components of understanding a patient's pulmonary condition.' Tobacco use is a primary example of this — patients who currently smoke or have smoked in the past are going to be more susceptible to respiratory conditions of all kinds. 'Though cigarette use has declined in most places across the country, tobacco use still has a significant impact on our nation's health,' said Marshall. 'Tobacco use contributes to many diseases, including asthma, COPD, heart disease, and, of course, cancer. Current and former smokers are also at a significantly increased risk of infections, namely the development of pneumonia.' In addition, patients with a history of smoking are more likely to be hospitalized and die from pneumonia, he said. Physicians should also consider their patients' work history, hobbies, and current occupation. Patients who work in certain occupations, like construction, for instance, may have exposure to harmful substances, like asbestos or certain paints. Chronic exposure may lead to complications and can be a good starting point for diagnosis. Even living in an area with high pollution and poor air quality can be a contributing factor. Patients will present with both acute and chronic symptoms, ranging from cough to shortness of breath, exercise-induced asthma, allergies, and sleep apnea. After taking a comprehensive history, physicians can utilize a variety of tools for further diagnosis — one of which could include pulse oximetry. 'Though patients typically present with symptoms prior to ever becoming hypoxemic, it may be helpful to get a walking pulse oximetry to understand the degree of changes in SpO2 and heart rate with exertion,' said Marshall. 'Simply walking a patient with a pulse oximeter can provide helpful information regarding exercise tolerance and whether that patient needs oxygen.' Physicians might also want to try a handheld spirometer, which is simple to use and provides a good deal of information regarding patients' pulmonary and respiratory health. 'Spirometers can provide you with a basic set of numbers right in the office,' said Orlando Ruiz-Rodriguez, MD, a pulmonologist at Orlando Health in Orlando, Florida. A basic stethoscope can also help in diagnosing pulmonary issues. 'Listening to lungs is part of the standard of care,' said Ruiz-Rodriguez. 'Make sure there are no abnormal sounds, like wheezing, crackling, or decreased breathing. Today's generation of stethoscopes are electronic and a much-improved tool at the primary care level.' There are other tests PCPs can explore before deciding it's time to seek out a specialist. 'To expedite workup and management of patients with lung diseases, pulmonologists typically prefer certain baseline tests before a referral,' said Kulkarni. 'These commonly include pulmonary function tests to assess airflow obstruction or restriction, chest imaging (chest x-ray or high-resolution CT if interstitial lung disease is suspected), and basic lab work such as CBC [complete blood count], CMP [comprehensive metabolic panel], and BNP [B-type natriuretic peptide test].' To help reduce diagnostic delays and improve patient outcomes, it's best to move with caution when considering a pulmonary fibrosis diagnosis, said Kulkarni. Pulmonary fibrosis is often challenging to diagnose because clinical presentation mimics common conditions like coronary artery disease and COPD, 'but it has worse clinical outcomes with delays in treatment,' she said. Beyond diagnostics, one consideration to keep in your toolkit, said Marshall, is vaccines. 'Patients with underlying respiratory or pulmonary conditions are at a higher risk of developing and becoming sick from respiratory illnesses,' he said. 'We now have several extraordinary vaccines available to our patients to help reduce the burden of infectious respiratory disease.' When to Refer While PCPs can treat respiratory issues in office to the best of their ability, there are times when referring to a pulmonologist is essential. 'Your local neighborhood pulmonologist is your friend,' said Marshall. 'Referrals to a pulmonologist should be considered whenever there is diagnostic uncertainty, when initial therapeutics are not working, or when more complex interventions or therapeutics are necessary in the workup and management of your patient.' A few common reasons to refer to a pulmonologist include treating or diagnosing unremitting cough or chronic refractory, he said. There are certain times when immediate referral is appropriate, according to Kulkarni. These include rapidly progressive dyspnea, hypoxia, hypercapnia, hemoptysis, suspected lung cancer, and large pleural effusions. For cases of symptom progression, she recommends referring with chronic coughs lasting over 8 weeks, unexplained or worsening dyspnea, frequent asthma or COPD exacerbations despite treatment, recurrent pneumonia, and signs of pulmonary hypertension. Referring should not be considered a last resort, either, said Ruiz-Rodriguez. 'Some primary care doctors want to do as much as possible before referring,' he said. 'But know the limitations of what you have available to you. If your patient has symptoms, abnormal test results, or even a complicated medical history, send them to us. Even sleep apnea with a complicated history is a cue to move on to a specialist.'
Yahoo
28 minutes ago
- Yahoo
Summer 2025 brings killer heat. Here are some surprising ways to stay safe.
Summer 2025 has arrived. It's starting off hot, and the forecast says get used to it. A hot summer isn't just uncomfortable — it's dangerous. Heat killed more people in the United States in 2024 than floods, tornadoes, wind or hurricanes, according to a report on weather-related fatalities published by the National Weather Service. The 30-year average tells the same story. Heat danger comes in many different forms. Sun exposure can damage your skin; sweating dehydrates you; humidity prevents sweat from doing its job; your body stops functioning property when it gets too hot. That can all quickly cascade into a life-threatening or deadly illness, even in otherwise healthy people. Some heat safety tips are obvious — but some are surprising. (Do you know how much water to drink while in the heat? It's probably more than you think.) Here's what to know: Keep your cool: Experts on how to stay safe, avoid sunburns in record-high temps Use sunblock or sunscreen: And reapply it regularly (every 2 hours is a good baseline.) Dress for the heat: Pick loose fitting, light colored and lightweight clothes, the National Weather Service recommends. Don't leave kids or pets in the car: The temperature quickly becomes deadly — even if it's not that hot outside. Check the weather: Your favorite weather app should have a wealth of information about UV index (for sunblock purposes), heat warnings and the feels-like temperature (more on why that's important below.) has additional information about the forecast and heat risk. Bring water: You'll need multiple bottles of water per person if you're spending extended time out in the sun. (How many bottles? Read more here.) Seek shade and air conditioning: Minimize your risk by staying cool and avoiding direct sun when you can. Know your risks: Heat is dangerous for everyone, but some people are more vulnerable than others. Being a child, over 65 or pregnant puts you at greater risk, the Centers for Disease Control and Prevention says. How long does sunscreen last? A guide to expiration dates, and if waterproof really works When the humidity is high, sweating isn't as effective at cooling the body. That makes it feel hotter than it is — and increases the danger. The heat index is a measure of how hot it really feels when relative humidity is factored in with the actual air temperature. When the heat index reaches 105 degrees or higher, conditions can quickly become dangerous for both people and pets. A lot. In Arizona, officials recommend drinking about 65 ounces of water a day, even if you're mostly indoors. It's even more urgent for people working outdoors in extreme heat. The Occupational Safety and Health Administration says outdoor workers should drink at least 8 ounces of water every 20 minutes, even if they're not thirsty. If you're drinking 16-ounce bottles of water, that would be 3 bottles every 2 hours. Your body may need to replenish electrolytes – but be careful about sugary or caffeinated drinks if you're trying to stay hydrated. Kelly Olino, assistant professor of surgical oncology at the Yale School of Medicine, previously told USA TODAY that people can dilute a bottle of Gatorade with water to replenish both water and replace salt losses from extended sweating. "In the extreme heat, with sweating, we're losing pure water, but we're also losing salt," she said. Excessive heat and humidity make it difficult for your body to regulate its temperature. Here are some of the signs and symptoms of heat illness, according to the CDC. The National Athletic Trainers' Association says heat stroke can quickly turn deadly. The association says to watch out for: Altered consciousness ("seizures, confusion, emotional instability, irrational behavior or decreased mental acuity") Nausea, vomiting, or diarrhea Headache, dizziness or weakness Increased heart rate Decreased blood pressure or fast breathing Dehydration Combativeness A person with a temperature around 104 degrees is in a life-threatening situation — they need immediate medical treatment. One incredibly effective treatment: An ice-filled tub. Contributing: Cybele Mayes-Osterman, USA TODAY; Raphael Romero Ruiz, Arizona Republic; Cheryl McCloud, Pensacola News Journal This article originally appeared on USA TODAY: Summer 2025 heat safety tips: How much water to drink and more
Fast Company
29 minutes ago
- Fast Company
Workplace mistreatment may affect observers as strongly as victims
Picture this: On your way out of the office, you notice a manager berating an employee. You assume the worker made some sort of mistake, but the manager's behavior seems unprofessional. Later, as you're preparing dinner, is the scene still weighing on you—or is it out of sight, out of mind? If you think you'd still be bothered, you're not alone. It turns out that simply observing mistreatment at work can have a surprisingly strong impact on people, even for those not directly involved. That's according to new research led by Edwyna Hill, coauthored by Rachel Burgess, Manuela Priesemuth, Jefferson McClain, and me, published in the Journal of Applied Psychology. Using a method called meta-analysis —which takes results from many different studies and combines them to produce an overall set of findings—we reviewed the growing body of research on what management professors like me call 'third-party perceptions of mistreatment.' In this context, 'third parties' are people who observe mistreatment between a perpetrator and the victim, who are the first and second parties. We looked at 158 studies published in 105 journal articles involving thousands of participants. Those studies explored a number of different forms of workplace mistreatment ranging from incivility to abusive supervision and sexual harassment. Some of those studies took part in actual workplaces, while others examined mistreatment in tightly controlled laboratory settings. The results were striking: We found that observing a coworker being mistreated on the job has significant effects on the observers' emotions. In fact, we found that observers of mistreatment may be as affected by what happened as the people actually involved in the event. These reactions fall along a spectrum—some helpful, others less so. On the encouraging side, we found that observers tend to judge perpetrators and feel empathy for victims. These reactions discourage mistreatment by creating a climate that favors the victim. On the other hand, we found that observers may also enjoy seeing their coworkers suffer—an emotion called schadenfreude —or blame the victim. These sorts of reactions damage team dynamics and discourage people from reporting mistreatment. Why it matters These findings matter because mistreatment in the workplace is disturbingly common, and even more frequently observed than experienced. One recent study found that 34% of employees have experienced workplace mistreatment firsthand, but 44% have observed it happening to someone else. In other words, nearly half of workers have likely seen a scenario like the one described at the start of this article. Unfortunately, the human resources playbook on workplace mistreatment rarely takes third parties into account. Some investigation occurs, potentially resulting in some punishment for the perpetrator and some support for the victim. A more effective response to workplace mistreatment would recognize that the harm often extends beyond the victim, and that observers may need support too. What still isn't known What's needed now is a better understanding of the nuances involved in observing mistreatment. Why do some observers react with empathy, while others derive pleasure from the suffering of others? And why might observers feel empathy for the victim but still respond by judging or blaming them? Answering these questions is a crucial next step for researchers and leaders seeking to design more effective workplace policies.
